These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 12738965)

  • 1. Future trends in the treatment of cognitive disorders.
    Kumari S; Ram VJ
    Drugs Today (Barc); 2001 Oct; 37(10):675-689. PubMed ID: 12738965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the Development of Abeta-Related Therapeutic Strategies for Alzheimer's Disease.
    Barrow CJ
    Drug News Perspect; 2002 Mar; 15(2):102-109. PubMed ID: 12677216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NIH state-of-the-science conference statement: Preventing Alzheimer's disease and cognitive decline.
    Daviglus ML; Bell CC; Berrettini W; Bowen PE; Connolly ES; Cox NJ; Dunbar-Jacob JM; Granieri EC; Hunt G; McGarry K; Patel D; Potosky AL; Sanders-Bush E; Silberberg D; Trevisan M
    NIH Consens State Sci Statements; 2010 Apr; 27(4):1-30. PubMed ID: 20445638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective Molecules in Alzheimer's Disease: Therapeutic Antibodies.
    Solomon B
    Drug News Perspect; 2002 Sep; 15(7):410-416. PubMed ID: 12677176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Awareness disorders in Alzheimer's disease and in mild cognitive impairment].
    Jacus JP; Dupont MP; Herades Y; Pelix C; Large H; Baud M
    Encephale; 2014 Apr; 40(2):180-7. PubMed ID: 24630532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.
    Abdelnour C; van Steenoven I; Londos E; Blanc F; Auestad B; Kramberger MG; Zetterberg H; Mollenhauer B; Boada M; Aarsland D;
    Mov Disord; 2016 Aug; 31(8):1203-8. PubMed ID: 27296778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular Amyloidosis in Neurodegenerative Conditions.
    Matsubara E; Shoji M; Abe K; Frangione B; Ghiso J
    Drug News Perspect; 2002 Sep; 15(7):439-444. PubMed ID: 12677179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Late life depression or prodromal Alzheimer's disease: Which tools for the differential diagnosis?].
    Gasser AI; Salamin V; Zumbach S
    Encephale; 2018 Feb; 44(1):52-58. PubMed ID: 28434642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compensatory mechanisms in higher-educated subjects with Alzheimer's disease: a study of 20 years of cognitive decline.
    Amieva H; Mokri H; Le Goff M; Meillon C; Jacqmin-Gadda H; Foubert-Samier A; Orgogozo JM; Stern Y; Dartigues JF
    Brain; 2014 Apr; 137(Pt 4):1167-75. PubMed ID: 24578544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piracetam for dementia or cognitive impairment.
    Flicker L; Grimley Evans J
    Cochrane Database Syst Rev; 2000; (2):CD001011. PubMed ID: 10796585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving Alzheimer's Disease-Related Cognitive Deficits with sigma1 Receptor Agonists.
    Maurice T
    Drug News Perspect; 2002 Dec; 15(10):617-625. PubMed ID: 12677246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Science of Vascular Contributions to Cognitive Impairment and Dementia (VCID): A Framework for Advancing Research Priorities in the Cerebrovascular Biology of Cognitive Decline.
    Corriveau RA; Bosetti F; Emr M; Gladman JT; Koenig JI; Moy CS; Pahigiannis K; Waddy SP; Koroshetz W
    Cell Mol Neurobiol; 2016 Mar; 36(2):281-8. PubMed ID: 27095366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
    Small G; Erkinjuntti T; Kurz A; Lilienfeld S
    CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donepezil for vascular cognitive impairment.
    Malouf R; Birks J
    Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropsychology in Alzheimer's disease and other dementia research.
    Savla GN; Palmer BW
    Curr Opin Psychiatry; 2005 Nov; 18(6):621-7. PubMed ID: 16639085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive correlates of α4β2 nicotinic acetylcholine receptors in mild Alzheimer's dementia.
    Sabri O; Meyer PM; Gräf S; Hesse S; Wilke S; Becker GA; Rullmann M; Patt M; Luthardt J; Wagenknecht G; Hoepping A; Smits R; Franke A; Sattler B; Tiepolt S; Fischer S; Deuther-Conrad W; Hegerl U; Barthel H; Schönknecht P; Brust P
    Brain; 2018 Jun; 141(6):1840-1854. PubMed ID: 29672680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.
    Jellinger KA
    J Neural Transm (Vienna); 2018 Apr; 125(4):615-650. PubMed ID: 29222591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivastigmine for Alzheimer's disease.
    Birks J; Iakovidou V; Tsolaki M
    Cochrane Database Syst Rev; 2000; (2):CD001191. PubMed ID: 10796621
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.